



GENITOURINARY CANCERS

Selecting the Optimal Treatment Approach for Patients with Metastatic Prostate Cancer

Presented by: Sandy Srinivas, MD, *Stanford Cancer Institute*

Overview: Patients with metastatic prostate cancer have many treatment options in both the castration-sensitive and the castration-resistant settings, and there are many disease characteristics that impact therapy decisions. It is crucial to understand when to integrate PSMA-PET imaging, how much treatment intensification is appropriate for individual patients, when prostate-directed and/or metastasis-directed therapy may be appropriate, and whether to give certain therapies concurrently or sequentially.

Learning Objectives:

- Review the characteristics of metastatic castration-sensitive prostate cancer that influence appropriate treatment options, including radiation to the primary tumor, metastasis-directed therapy, and treatment intensification with chemotherapy.
- Explain when it is appropriate to perform PSMA-PET imaging and how to integrate PSMA-PET imaging results into the care of patients with castration-sensitive and castration-resistant metastatic prostate cancer.

Integrating New and Emerging Treatments into Bladder Cancer Care

Presented by:

Thomas W. Flaig, MD, *University of Colorado Cancer Center*

Charles C. Peyton, MD, *O'Neal Comprehensive Cancer Center at UAB*

Overview: Recent approvals and clinical trial results continue to enhance the treatment landscape for patients with non-muscle-invasive and muscle-invasive bladder cancer. This session provides important information in these recent updates, as well as how best to apply them to clinical practice.

Learning Objectives:

- Describe the new and emerging therapeutic options for patients with non-muscle-invasive bladder cancer and muscle-invasive bladder cancer.
- Discuss how recent updates to the treatment of bladder cancer can be integrated into clinical practice.

From Guidelines to Practice: Systemic Therapy Strategies in Advanced Renal Cell Carcinoma

Presented by: Naomi B. Haas, MD, *Abramson Cancer Center at the University of Pennsylvania*

Overview: The treatment landscape for advanced RCC includes several tyrosine kinase inhibitors and immunotherapies and continues to evolve. This session provides information for optimizing treatment and determining treatment sequencing for patients with RCC.

Learning Objectives:

- Evaluate the available evidence, guideline recommendations, and ongoing clinical trial data for systemic therapy options for the treatment of patients with advanced renal cell carcinoma.
- Integrate strategies for appropriate selection and sequencing of recommended therapy options for advanced renal cell carcinoma.